Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats

The New York Times - Business:

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.

Author: Rebecca Robbins and Dani Blum

This post first appeared in The New York Times - Business. Read the original article.